KA
PTCT icon

Kerrisdale Advisers’s PTC Therapeutics PTCT Stock Holding History

Kerrisdale Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-40,122
Closed -$1.35M – 15
2018
Q2 		$1.35M Buy
40,122
+4,557
+13% +$142K 0.56% 11
2018
Q1 		$962K Buy
35,565
+565
+2% +$14.3K 0.67% 13
2017
Q4 		$584K Buy
+35,000
New +$592K 1.18% 8

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Kerrisdale Advisers's PTCT Position: Q3 2018 in Review

Kerrisdale Advisers sold out of PTC Therapeutics (PTCT) in Q3 2018, closing a stake of 40,122 shares — an estimated $1.35M sold.

Kerrisdale Advisers first reported a position in PTCT in Q4 2017 and held it in 3 quarters. The position peaked at $1.35M in Q2 2018. 180 funds tracked by Wall St. Rank hold PTCT as of Q3 2018.

  • Kerrisdale Advisers reported no remaining PTC Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Kerrisdale Advisers sold 40,122 PTC Therapeutics shares in Q3 2018, an estimated $1.35M.
  • Kerrisdale Advisers first reported a position in PTC Therapeutics in Q4 2017 and held it in 3 quarters.
  • Kerrisdale Advisers's PTC Therapeutics position peaked at $1.35M in Q2 2018.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2018.

Based on Kerrisdale Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.